Bifogade filer
PDF
Kurs
-9,09%
Likviditet
0,00 MSEK
Kalender
| Tid* | ||
| 2025-02-21 | 08:30 | Bokslutskommuniké 2024 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-19 | - | Årsstämma |
| 2024-04-19 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-20 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2023-04-19 | - | Årsstämma |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-10 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2022-04-20 | - | Årsstämma |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-04 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2021-06-03 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-08-25 | - | Kvartalsrapport 2020-Q2 |
| 2020-02-27 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2020-02-26 | - | Årsstämma |
| 2020-02-04 | - | Bokslutskommuniké 2019 |
| 2019-05-08 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2019-05-07 | - | Årsstämma |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-08-10 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-03 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2018-05-02 | - | Årsstämma |
| 2018-02-23 | - | Bokslutskommuniké 2017 |
| 2017-08-11 | - | Kvartalsrapport 2017-Q2 |
| 2017-03-21 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2017-03-20 | - | Årsstämma |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2016-11-04 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-04 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-04 | - | X-dag ordinarie utdelning CLINE B 0.00 SEK |
| 2016-05-03 | - | Kvartalsrapport 2016-Q1 |
| 2015-11-06 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-06 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
With today's cost structure, Cline Scientific AB's (publ) expects to have cash until August 2024.
The Board intends to work diligently on finding solutions to strengthen the Company's long-term financial situation.
As previously communicated, the company has applied to participate in the EIC Accelerator program. The result from the latest step in the application process was a rejection due to the company being a couple of points below the limit required to move forward in the application process. The company will appeal the decision. Though, even if the company is successful with the appeal, it is the board's assessment that further measures still need to be taken to strengthen the company's long-term financial position.
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 0703585088
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.
This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 7.15pm CEST on 18 Jan 2024.
Pepparedsleden 1
AstraZeneca BioVentureHub Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com